News
08-05-2010, 12:05 AM
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period and fiscal year ended June 30, 2010.
More... (http://www.news-medical.net/news/20100805/ImmunoGen-fourth-quarter-2010-net-loss-increases-to-24134-million.aspx)
More... (http://www.news-medical.net/news/20100805/ImmunoGen-fourth-quarter-2010-net-loss-increases-to-24134-million.aspx)